December 2022 New Models & Upcoming events
News & Insights
Biocytogen’s target humanized mice offer an alternative to NHPs to support IND approval, not only when NHPs are in short supply, but also when NHPs are not relevant for some drug evaluations. Read More
Biocytogen currently offers Beacon®-based and FACS-based single B cell cloning discovery platforms - our antibody discovery team can help evaluate your project, make recommendations, and answer any questions regarding intellectual property, deliverables, and further development. Read More
Recommended by LinkedIn
The phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001 (CTLA-4 antibody), envafolimab (PD-L1 antibody) and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma. In addition, the trial will assess the safety and efficacy of the doublet combination of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma. Read More
Biocytogen has entered into an evaluation and option agreement with ADC therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development. Read More
Upcoming Events
Date: December 17th, 2022
Meet with our experts for an overview on Biocytogen’s in vivo pharmacology services focused on efficacy evaluation of novel therapeutics. Schedule a Meeting
Dates: December 19th-22nd, 2022
Join us to discover how our cutting-edge gene editing technologies can facilitate accelerated custom model generation. Meet with us
Dates: January 24th-26th, 2023
With a strong focus on immuno-oncology applications, stop by our booth to learn more about our in vivo efficacy, PK/PD, toxicity, and in vitro pharmacology platforms.